Sherley's Rheumatine Tablets for Adult Dogs, 120 mg

Summary of Product characteristics

                                Revised 26 November 2008
AN: 00256/2008
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Sherley’s Rheumatine Tablets for Adult Dogs, 120 mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance
mg/tablet
Aspirin
120.0
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Tablet.
A white to off-white circular, bi-convex tablet embossed on one face
with an
incomplete breakline.
4.
CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs over 6 weeks of age.
4.2INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the relief of pain associated with locomotion and the treatment of
joint
disease (including osteo-arthritis but excluding rheumatoid arthritis)
in
adult dogs.
4.3 CONTRA-INDICATIONS
Not for use on cats.
Not for use in pregnant female dogs.
Dosing should be stopped if signs of gastric irritation or vomiting
occur.
Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as
there is a potential risk of increased renal toxicity.
Do not administer other NSAIDs concurrently or within 24 hours of each
other.
Since many NSAIDs are highly bound to plasma proteins they may
compete with other highly bound drugs, which may lead to toxic
effects.
Due to possible toxic effects on the kidneys, concurrent use or use
within
24 hours of an aminoglycoside antimicrobial or methoxyfluorane
anaesthesia should be avoided.
Avoid use in any animal less than 6 weeks of age or in aged dogs. If
such
use cannot be avoided animals may require a reduced dose and careful
clinical management.
Use is contra-indicated in animals suffering from cardiac, hepatic, or
renal
disease, where there is the possibility of gastro-intestinal
ulceration or
bleeding, or where there is evidence of hypersensitivity to the
product.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Revised 26 November 2008
AN: 00256/2008
4.5SPECIAL PRECAUTIONS FOR USE
(I)
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Do not exceed the stated dose or the duration of treatment.
(II)
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON AD
                                
                                Read the complete document